{"url_path":"/sec/qure/8-k/2026-06-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **                        **Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1590560/0001104659-26-076044-index.html","accession_number":"0001104659-26-076044","cik":"0001590560","ticker":"QURE","issuer_name":"uniQure N.V.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590560/0001104659-26-076044-index.html","primary_entity_key":"0001590560","primary_entity_name":"uniQure N.V."},"word_count":161,"has_tables":true,"body_markdown":"**Item 8.01**                        **Other Events.**\n\nOn June 19, 2026, the Company announced preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. As of the May 29, 2026 data cutoff date, three of six patients in the first, low-dose cohort (1x1012 gc/mL) achieved meaningful reductions in disabling seizures during months four through six of follow-up, ranging from a 79% to 100% decline from baseline. The remaining three patients in the low-dose cohort experienced variable changes in disabling seizures during months four through six of follow-up, ranging from a 33% decrease to a 36% increase compared to baseline. As of June 19, 2026, there have been no serious adverse events related to AMT-260 or the surgical procedure reported. All reported adverse events in the low dose cohort were classified as mild or moderate in severity, with the most common adverse event being headache (N=2). No immunosuppression was required.\n\n​"}